Hormone Resistant Prostate Cancer Completed Phase Trials for Cabozantinib (DB08875)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01812668Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate CancerTreatment